2 results
Approved WMOWill not start
The primary objective of this study is to determine if there is an improvement in progression-free survival(PFS) when siltuximab is added to VELCADE* (bortezomib) and dexamethasone in subjects with relapsedor refractory multiple myeloma.The…
Approved WMOCompleted
The study has two objectives. Firstly, we will investigate the safety and tolerability of the study drug following administration of a single escalating dose of the drug. Secondly, we will investigate the rate at which the study drug is absorbed…